


MEFLUVAC™

H5 PLUS 8

TRANSBOUNDARY
CONTROL



Inactivated trivalent vaccine for immunization against Highly Pathogenic Avian Influenza H5 subtypes.

INTRODUCTION

Highly pathogenic avian influenza (HPAI) is an extremely contagious, multi-organ systemic disease leading to high mortality in poultry¹. The disease is caused by some H5 and H7 subtypes of type A influenza virus, family *Orthomyxoviridae*.¹ These HPAI viruses can develop from certain LPAI viruses, usually while they are circulating in poultry flocks.²

HPAI viruses can cause mortality in 90-100% of the flock, and trigger epidemics that may spread rapidly, devastate the poultry industry and result in severe trade restrictions.²

Avian influenza virus can spread in the flock by the fecal-oral and aerosol routes. In addition, fomites can play an important role in the transmission and flies may act as mechanical vectors.²

Highly pathogenic avian influenza viruses have been found in the yolk and albumen of eggs from infected chickens, turkeys and quails.²

Field results indicate that movement control, systematic surveillance for wild birds, serological monitoring in commercial poultry, complemented with biosecurity measures and vaccination, are crucial to mitigate the impact caused by HPAI strains.³

COMPOSITION (before inactivation)

- Inactivated Avian Influenza H5N1 subtype, clade 2.2.1.2 [A/Chicken/Egypt/ RG-173 CAL/2017(H5N1)] $\geq 8.5 \log_{10} \text{EID}_{50} / \text{dose}$.
- Inactivated Avian Influenza H5N1 subtype, clade 2.2.1.1 [RgA/CK/Egypt/ME1010/2016(H5N1)] $\geq 8.5 \log_{10} \text{EID}_{50} / \text{dose}$.
- Inactivated Avian Influenza H5N8 subtype clade 2.3.4.4b [rgA/chicken/ME-2018/H5N8] $\geq 8.5 \log_{10} \text{EID}_{50} / \text{dose}$.

TARGET SPECIES

Chickens.

INDICATIONS

For immunization of commercial poultry against Highly Pathogenic Avian Influenza H5N1 & H5N8 subtypes.

VACCINATION PROGRAM

Birds can be vaccinated from seven days of age onwards, as per advice from your poultry veterinarian.

IMMUNITY

- Onset of immunity: 3 weeks after the first vaccination.
- Duration of immunity: conditioned to the vaccination scheme established for the local epidemiological situation.

WITHDRAWAL

Zero days.

ADDITIONAL FEATURES

Efficacy against highly pathogenic Avian Influenza strains belonging to subtype H5N6 clade 2.3.4.4g.⁴

DOSAGE

The vaccine dose (0.5 mL/bird) should be administered subcutaneously in the lower part of the neck or intramuscularly in the thigh or breast muscles.

MEFLUVAC™

H5 PLUS 8

TRANSBOUNDARY
CONTROL



Inactivated trivalent vaccine for immunization against Highly Pathogenic Avian Influenza H5 subtypes.



PRESENTATION

MEFLUVAC™ H5 PLUS 8 is packed and presented in 500 mL (1000 doses) polyethylene terephthalate (PET) bottles.

ADMINISTRATION

Before use, the vaccine should be shaken well to ensure proper mixing. Sterile injection equipment should be used to avoid contamination.

- Subcutaneous injection: apply in the lower part of the neck. The needle should be inserted just under the skin in a direction away from the head and in a straight line with the neck.
- Intramuscular injection: when applied in the breast muscles the needle must be inserted with a 45° angle to avoid intraperitoneal injection.

STORAGE PRECAUTIONS

- Store and transport refrigerated (+2°C to +8°C).
- Do not freeze.
- Store in a dry place protected from direct sunlight.
- Do not use this product after the expiry date.
- Shelf life after first opening the bottle: 3 hours.

References

1. Swayne DE, Suarez DL. Highly pathogenic avian influenza. *Rev Sci Tech*. 2000 Aug;19(2):463-82. doi: 10.20506/rst.19.2.1230. PMID: 10935274.
2. The Center for Food Security and Public Health, November 2015, Avian Influenza Fowl Plague, Grippe Aviaire.
3. A. Anis, M. AboElkhair, M. Ibrahim, Characterization of highly pathogenic avian influenza H5N8 virus from Egyptian domestic waterfowl in 2017, *Avian Pathol.* (2018), <https://doi.org/10.1080/03079457.2018.1470606>.
4. TL-22-20110.

For further information please contact us:

kemin.biologics@kemin.com

or visit:

kemin.com/eu/en/markets/vaccines



Kemin Industries, Inc. and its group of companies 2025. All rights reserved. ®™ Trademark of Kemin Industries, Inc., U.S.A. Certain statements, product labelling and claims may differ by geography or as required by local governmental regulations.

PTP-11616

KEMIN
Compelled by Curiosity™